FOLH1 and prostate carcinoma: For example, Prive et al. compared [89Zr]Zr-DOTA-PSMA-617 and [89Zr]Zr-DOTA-PSMA-I&T with [177Lu]Lu-DOTA-PSMA-617 and [177Lu]Lu-DOTA-PSMA-I&T, respectively, in a mouse model of PSMA+/- prostate cancer [28].